

<ion-view title="Acerca de DIABETapp" id="page7">

    <div class="bar bar-subheader cal-4">
        <h2 class="title negro">Bibliografía Tratamiento antidiabético</h2>
    </div>

    <ion-content padding="false" class="has-header" >
        <div class="spacer" style="width: 300px; height: 40px;"></div>

        <div style="padding: 20px;" class="bibliografia">
            <ol>
                <ol>
                    <li >Ryd&eacute;n L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-87.&nbsp;</li>
                    <li >Castro A, Marzal D, Tejera C, Dalmau R, Garc&iacute;a-Moll X, G&oacute;mez-Doblas JJ, et al. Actualizaci&oacute;n del tratamiento antidiab&eacute;tico en el paciente con enfermedad cardiovascular. 1.&ordf; ed. Sociedad Espa&ntilde;ola de Cardiolog&iacute;a; 2016.</li>
                    <li >Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J 2016;37:2315-81.&nbsp;</li>
                    <li >Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016;37:2999-3058.</li>
                    <li >Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. Endocr Pract 2017;23:207-38.&nbsp;</li>
                    <li >Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.&nbsp;</li>
                    <li >UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-65.</li>
                    <li >Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15(10):938-53.</li>
                    <li >Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290(4):486-94.&nbsp;</li>
                    <li >Holman RR, Bethel MA, Chan JCN, Chiasson JL, Doran Z, Ge J, et al. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am Heart J 2014;168(1):23-9.e2.</li>
                    <li >McGuire DK, Inzucchi SE. New drugs for the treatment of diabetes mellitus: part I: thiazolidinediones and their evolving cardiovascular implications. Circulation 2008;117(3):440-9.</li>
                    <li >White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369(14):1327-35.</li>
                    <li >Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369(14):1317-26.&nbsp;</li>
                    <li >Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al.; for the TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015;373(3):232-42.&nbsp;</li>
                    <li >McInnes G, Evans M, Del Prato S, Stumvoll M, Schweizer A, Lukashevich V, et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab 2015;17(11):1085-92.</li>
                    <li >Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373(22):2117-28.&nbsp;</li>
                    <li >Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016;375(4):323-34.</li>
                    <li >Neal B, Perkovi B, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. June 12, 2017 NEJM.org.DOI: 10.1056/NEJMoa1611925.</li>
                    <li >Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K&oslash;ber LV, et al.; for the ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373(23):2247-57.&nbsp;</li>
                    <li >Marso SP, Daniels GH, BrownFrandsen K, Kristensen P, Mann JFE, Nauck MA, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375(4):311-22.&nbsp;</li>
                    <li >Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-44.</li>
                    <li >ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, D&iacute;az R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367(4):319-28.</li>
                    <li >Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. Am Heart J 2016;179:175-83.</li>
                    <li >Marso SP, McGuire DK, Zinman B, Poulter NR, Sci FM, Emerson SS, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. June 12, 2017DOI: 10.1056/NEJMoa1615692.</li>
                    <li >American Diabetes Association. Standard of medical care in diabetes 2017. Diabetes Care 2017;40(Suppl 1):S1-S2.&nbsp;</li>
                    <li >UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.&nbsp;</li>
                    <li >Holman R, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577- 89.&nbsp;</li>
                    <li >IDF Clinical Guideline Development Group. Global Guideline for Type 2 Diabetes. Bruselas, B&eacute;lgica: International Diabetes Federation; 2012.&nbsp;<span class="s3">Disponible en: </span>http://www.idf.org/global-guideline-type-2-diabetes-2012 (acceso: 25 de junio de 2014<span class="s3">).</span></li>
                    <li >IDF Clinical Guideline Development Group. Guideline for management of post meal glucose. Bruselas, B&eacute;lgica: International Diabetes Federation;&nbsp;<span class="s3">2011. Disponible en: </span>http://www.idf.org/2011-guideline-managementpostmeal-glucose-diabetes (acceso: 25 de junio de 2014<span class="s3">).</span></li>
                    <li >Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.</li>
                    <li >Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9.&nbsp;</li>
                    <li >Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Can J Diabetes 2016;40(3):193-5.</li>
                    <li >Standard of medical care in diabetes ADA/EASD 2015. Diabetes Care 2015;38:140-49.</li>
                    <li >Ericsson &Aring;, Lundqvist A. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden. Appl Health Econ Health Policy 2017;15:237-48.&nbsp;</li>
                    <li >Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Monoterapia con insulina versus combinaciones de insulina con agentes hipoglucemiantes orales para pacientes con diabetes mellitus tipo 2 (Revisi&oacute;n Cochrane traducida). En: La Biblioteca Cochrane Plus, 2004 N&uacute;mero 2. Oxford: Update Software Ltd. Disponible en: http://www.bibliotecacochrane.com/BCPGetDocument.asp SessionID=9310380&amp;DocumentID=CD003418. (Traducida de The Cochrane Library, 2004 Issue 2. Chichester, UK: John Wiley &amp; Sons, Ltd.).&nbsp;</li>
                    <li >Rendell M. Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile. Drugs Today (Barc) 2013;49(6):387-97.&nbsp;</li>
                    <li >Vilsb&oslash;ll T, Rosenstock J, Yki-J&auml;rvinen H, Cefalu WT, Chen Y, Luo E, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-77.&nbsp;</li>
                    <li >Use JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12.&nbsp;</li>
                    <li >DeVries JH, Bain SC, Rodbard HW, Seufert J, D&rsquo;lessio D, Thomsen AB, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012;35:1446-54.</li>
                    <li >Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-42.</li>
                </ol>
        </div>

        <div class="spacer" style="width: 300px; height: 20px;"></div>

    </ion-content>


</ion-view>
